Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2018  |  Volume : 14  |  Issue : 4  |  Page : 772-779

Conversion chemotherapy with capecitabine and oxaliplatin for colorectal cancer with potentially resectable liver metastases: A phase II, open-label, single-arm study

1 Department of Gastrointestional Surgery, Guandong General Hospital, Guangzhou, Guangdong, China
2 Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
3 Department of Gastrointestional Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
4 Department of Hepato-Pancreato-Biliary Surgery, Beijing Cancer Hospital and Institute, Beijing, China
5 Research Institute of General Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China
6 Department of General surgery, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital With Nanjing Medical University, Nanjing, Jiangsu, China
7 Department of Colorectal surgery, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
8 Department of Colorectal surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
9 Department of Medical Oncology, Anhui Provincial Hospital, Hefei, Anhui, China
10 Department of Colorectal Surgery, The Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
11 Department of Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Correspondence Address:
Feng Lin
The Sixth Affiliated Hospital, Sun-Yat Sen University, 26, Yuan Cun Er Heng Lu, Tianhe Qu, Guangzhou, Guangdong 510655
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_738_17

Rights and Permissions

Aim: The aim of this is study is to assess the efficacy and safety of conversion capecitabine plus oxaliplatin (XELOX) in Chinese patients with potentially resectable colorectal liver metastases (CLMs). Patients and Methods: Thirty patients (median age 57.5 years) with potentially resectable CLMs were treated with XELOX in a single-arm, open-label, nonrandomized, multicenter clinical trial. Results: The objective response rate in the 30 patients was 40% (95% confidence interval: 22.7%–59.4%), and the rate of conversion to resectable CLMs was 43.3%. Patients who underwent liver resection (n = 11) had a longer median progression-free survival and overall survival than those who did not. XELOX showed an acceptable safety profile. Conclusion: XELOX may effectively convert potentially resectable CLM into resectable CLM, providing survival benefits with a favorable safety profile. Clinical Trials.gov identifier: NCT 00997685.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded80    
    Comments [Add]    

Recommend this journal